EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MEK1/2 inhibition decreases pro-inflammatory responses in macrophages from people with cystic fibrosis and mitigates severity of illness in experimental murine methicillin-resistant Staphylococcus aureus infection

Mithu De, Gregory Serpa, Eryn Zuiker, Katherine B Hisert, W Conrad Liles, Anne M Manicone, Emily A Hemann, Matthew E Long

Frontiers in Cellular and Infection Microbiology · 2024

DOI: 10.3389/fcimb.2024.1275940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Mithu De und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, OH, United States. Hauptthemen laut MEDLINE: Cystic Fibrosis, Methicillin-Resistant Staphylococcus aureus, Benzamides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic pulmonary bacterial infections and associated inflammation remain a cause of morbidity and mortality in people with cystic fibrosis (PwCF) despite new modulator therapies. Therapies targeting host factors that dampen detrimental inflammation without suppressing immune responses critical for controlling infections remain limited, while the development of lung infections caused by antimicrobial resistant bacteria is an increasing global problem, and a significant challenge in CF. Pharmacological compounds targeting the mammalian MAPK proteins MEK1 and MEK2, referred to as MEK1/2 inhibitor compounds, have potential combined anti-microbial and anti-inflammatory effects. Here we examined the immunomodulatory properties of MEK1/2 inhibitor compounds PD0325901, trametinib, and CI-1040 on CF innate immune cells. Human CF macrophage and neutrophil phagocytic functions were assessed by quantifying phagocytosis of serum opsonized pHrodo red E. coli , Staphylococcus aureus , and zymosan bioparticles. MEK1/2 inhibitor compounds reduced CF macrophage pro-inflammatory cytokine production without impairing CF macrophage or neutrophil phagocytic abilities. Wild-type C57BL6/J and Cftr tm1kth (F508del homozygous) mice were used to evaluate the in vivo therapeutic potential of PD0325901 compared to vehicle treatment in an intranasal methicillin-resistant Staphylococcus aureus (MRSA) infection with the community-acquired MRSA strain USA300. In both wild-type and CF mice, PD0325901 reduced inflammation associated body mass loss. Wild-type mice treated with PD0325901 had significant reduction in neutrophil-mediated inflammation compared to vehicle treatment groups, with preserved clearance of bacteria in lung, liver, or spleen 1 day after infection in either wild-type or CF mouse models. In summary, this study provides the first data evaluating the therapeutic potential of MEK1/2 inhibitor to modulate CF immune cells and demonstrates that MEK1/2 inhibitors diminish pro-inflammatory responses without impairing host defense mechanisms required for acute pathogen clearance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisMethicillin-Resistant Staphylococcus aureusBenzamidesHumansAnimalsMiceEscherichia coliMacrophagesInflammationPatient AcuityMammalsDiphenylamine

Stichwörter der Autor:innen

S. aureuscystic fibrosismacrophageneutrophiltherapeutic

Substanzen

mirdametinibBenzamidesDiphenylamine

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, OH, United States.
  • Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, United States.
  • Department of Medicine, National Jewish Health, Denver, CO, United States.
  • Department of Medicine, Division of Infectious Diseases, University of Washington, Seattle, WA, United States.
  • Center for Lung Biology, University of Washington, Seattle, WA, United States.
  • Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA, United States.

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • NCATS NIH HHS
  • NCI NIH HHS
  • NIEHS NIH HHS
  • NIAID NIH HHS
  • Cystic Fibrosis Foundation
  • National Institutes of Health

Zitieren

APA

De, M., Serpa, G., Zuiker, E., Hisert, K. B., Liles, W. C., Manicone, A. M., Hemann, E. A., & Long, M. E. (2024). MEK1/2 inhibition decreases pro-inflammatory responses in macrophages from people with cystic fibrosis and mitigates severity of illness in experimental murine methicillin-resistant Staphylococcus aureus infection. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1275940

Vancouver

De M, Serpa G, Zuiker E, Hisert KB, Liles WC, Manicone AM, et al. MEK1/2 inhibition decreases pro-inflammatory responses in macrophages from people with cystic fibrosis and mitigates severity of illness in experimental murine methicillin-resistant Staphylococcus aureus infection. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1275940

BibTeX
@article{De2024,
  author = {De, Mithu and Serpa, Gregory and Zuiker, Eryn and Hisert, Katherine B and Liles, W Conrad and Manicone, Anne M and Hemann, Emily A and Long, Matthew E},
  title = {MEK1/2 inhibition decreases pro-inflammatory responses in macrophages from people with cystic fibrosis and mitigates severity of illness in experimental murine methicillin-resistant Staphylococcus aureus infection},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  doi = {10.3389/fcimb.2024.1275940}
}
Kostenlos starten →